Ptc Therapeutics (PTCT) Common Equity (2012 - 2026)
Ptc Therapeutics (PTCT) posted quarterly Common Equity of -$165.4 million for Q2 2026, up 19.94% year-over-year from -$137.9 million in Q2 2025, and up 8.37% quarter-over-quarter from -$180.5 million in Q1 2026.
Ptc Therapeutics (PTCT) Common Equity (2012 - 2026) Analysis & Trends
Ptc Therapeutics' Common Equity history runs 15 years deep, the most recent figure standing at -$165.4 million for Q2 2026.
- In Q2 2026, Common Equity rose 19.94% year-over-year to -$165.4 million; the TTM figure through Jun 2026 stood at -$165.4 million (up 19.94% YoY), while the FY2025 annual figure was -$205.3 million, up 81.3% from the prior year.
- Common Equity for Q2 2026 stood at -$165.4 million, up from -$180.5 million in the prior quarter.
- The five-year high for Common Equity was -$90.6 million in Q1 2022, with the low at -$1.1 billion in Q4 2024.
- The 5-year median for Common Equity is -$287.0 million (2022), against an average of -$472.2 million.
- The sharpest annual moves came in 2022 and 2025: Common Equity sank 24236.72% in 2022, then soared 85.23% in 2025.
- Ptc Therapeutics' Common Equity stood at -$347.1 million in 2022, then tumbled by 135.84% to -$818.6 million in 2023, then tumbled by 34.15% to -$1.1 billion in 2024, then surged by 81.3% to -$205.3 million in 2025, then rose by 19.46% to -$165.4 million in 2026.
- Business Quant data shows PTCT's Common Equity at -$165.4 million in Q2 2026, -$180.5 million in Q1 2026, and -$205.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Ptc Therapeutics | 5.97 Bn | 3.75 Bn | 340.60 Mn | -165.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -165.36 Mn |
| Mar 31, 2026 | -180.47 Mn |
| Dec 31, 2025 | -205.31 Mn |
| Sep 30, 2025 | -155.76 Mn |
| Jun 30, 2025 | -206.55 Mn |
| Mar 31, 2025 | -185.76 Mn |
| Dec 31, 2024 | -1.10 Bn |
| Sep 30, 2024 | -1.05 Bn |
| Jun 30, 2024 | -980.18 Mn |
| Mar 31, 2024 | -893.92 Mn |
| Dec 31, 2023 | -818.56 Mn |
| Sep 30, 2023 | -670.81 Mn |
| Jun 30, 2023 | -579.27 Mn |
| Mar 31, 2023 | -457.56 Mn |
| Dec 31, 2022 | -347.09 Mn |
| Sep 30, 2022 | -226.90 Mn |
| Jun 30, 2022 | -182.22 Mn |
| Mar 31, 2022 | -90.58 Mn |
| Dec 31, 2021 | 1.44 Mn |
| Sep 30, 2021 | 104.93 Mn |